Get the Stockscreener App
12.06
6.37%
-0.82
After Hours:
12.08
0.02
+0.17%
Armata Pharmaceuticals Inc stock is traded at $12.06, with a volume of 28,775.
It is down -6.37% in the last 24 hours and up +14.42% over the past month.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections in the United States. The company develops its products using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company is also developing and advancing synthetic phage for treating diseases caused by pseudomonas aeruginosa. Armata Pharmaceuticals, Inc. is headquartered in Marina del Rey, California.
See More
Previous Close:
$12.88
Open:
$12.87
24h Volume:
28,775
Relative Volume:
0.59
Market Cap:
$441.79M
Revenue:
$4.90M
Net Income/Loss:
$-173.80M
P/E Ratio:
-2.5193
EPS:
-4.787
Net Cash Flow:
$-26.31M
1W Performance:
-0.50%
1M Performance:
+14.42%
6M Performance:
+253.67%
1Y Performance:
+948.70%
1-Day Range:
$12.05
$13.18
1-Week Range:
$10.66
$13.22
52-Week Range:
$1.11
$16.34
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Name
Armata Pharmaceuticals Inc
Sector
Industry
Phone
310-655-2928
Address
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
12.06 | 471.83M | 4.90M | -173.80M | -26.31M | -4.787 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-19-19 | Initiated | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Stock (ARMP) Latest News
Buyback Watch: Is Armata Pharmaceuticals Inc a cyclical or defensive stock2026 Retail Activity & Daily Entry Point Trade Alerts - baoquankhu1.vn
Trend Report: Is Armata Pharmaceuticals Inc currently under institutional pressureWeekly Profit Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Earnings Beat: Is Armata Pharmaceuticals Inc currently under institutional pressure2026 Earnings Impact & Growth Oriented Trading Recommendations - baoquankhu1.vn
ARMP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Update Recap: What analysts say about Armata Pharmaceuticals Inc stockEarnings Risk Report & Long-Term Safe Investment Plans - baoquankhu1.vn
Armata Pharmaceuticals, Inc. (TG1N.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting - The Globe and Mail
Armata Pharmaceuticals schedules annual meeting for June 11 - Investing.com
Armata Pharmaceuticals schedules annual meeting for June 11 By Investing.com - Investing.com India
Armata Pharmaceuticals sets June 11, 2026 for annual stockholders meeting - TradingView — Track All Markets
ARMP Technical Analysis & Stock Price Forecast - Intellectia AI
Market Outlook: Is Armata Pharmaceuticals Inc stock a smart retirement pick2026 Volume Leaders & Verified Swing Trading Watchlists - baoquankhu1.vn
Innoviva (INVA) files 10-K/A adding Armata audited financials and new officer certifications - stocktitan.net
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Armata Pharmaceuticals stock edges down on fourth quarter earnings miss By Investing.com - Investing.com Australia
Armata Pharmaceuticals stock edges down on fourth quarter earnings miss - Investing.com
Armata Pharmaceuticals Reports $173.8 Million Net Loss for 2025 Amid Convertible Loan Impact and Impairment Charges - Minichart
ARMP Reports Decrease in Grant Revenue for Q4 2025 - GuruFocus
Armata Pharmaceuticals: Advancing Bacteriophage Therapies for Antibiotic-Resistant Bacterial Infections in 2025 - Minichart
Armata Pharmaceuticals (ARMP) Q4 and Full-Year 2025 Earnings: Revenue Beat, Net Loss Hits $173.8M - Bayelsa Watch
Breakout Watch: Is Armata Pharmaceuticals Inc a cyclical or defensive stockPrice Action & AI Powered Market Trend Analysis - baoquankhu1.vn
ARMATA PHARMACEUTICALS, INC._December 31, 2025 - SEC.gov
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results - Finviz
Armata Pharmaceuticals (NASDAQ: ARMP) advances late-stage phage pipeline with new funding - Stock Titan
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
ARMP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Armata Pharmaceuticals Reports Positive Phase 2a Study Results - MSN
HC Wainwright reaffirms buy on Armata Pharmaceuticals, Inc. (ARMP) after FDA nod - MSN
Armata Pharmaceuticals delays Q4 2025 results, gets FDA approval By Investing.com - Investing.com India
Armata Pharmaceuticals (ARMP) Delays Financial Results Release - GuruFocus
Armata Pharmaceuticals delays announcement of fourth quarter and full-year 2025 results and provides corporate update - marketscreener.com
Armata Pharmaceuticals delays Q4 2025 results, gets FDA approval - Investing.com
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update - Finviz
Armata Highlights AP-SA02 Progress Amid Earnings Release Delay - tipranks.com
Armata Pharmaceuticals delays 2025 results, wins QIDP and readies Phase 3 for AP-SA02 - TradingView
Armata Pharmaceuticals (ARMP) delays 2025 results, advances AP-SA02 toward Phase 3 - Stock Titan
Armata pushes back earnings as FDA backs Phase 3 staph blood infection study - Stock Titan
Armata Pharmaceuticals (ARMP) CBO reports tax-withheld share disposition - Stock Titan
Armata (ARMP) CEO Birx has 4,919 RSU shares withheld for tax obligations - Stock Titan
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape - The Manila Times
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags - Seeking Alpha
Armata Pharmaceuticals (ARMP) Projected to Post Earnings on Thursday - MarketBeat
Director at Armata (NASDAQ: ARMP) receives 25,640 stock options grant - Stock Titan
Armata (NASDAQ: ARMP) director receives 25,640 stock options at $11.61 strike - Stock Titan
[Form 4] Armata Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Armata Pharmaceuticals (ARMP) grants director 25,640 stock options - Stock Titan
Armata Pharmaceuticals (ARMP) director granted 25,640 stock options - Stock Titan
Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update - GuruFocus
Published on: 2026-03-08 06:18:18 - baoquankhu1.vn
Will Armata Pharmaceuticals Inc. stock return to pre crisis levelsNew Guidance & Risk Controlled Swing Alerts - Naître et grandir
Armata Pharmaceuticals Inc Stock (ARMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):